

People

Appointments

GANYMED Pharmaceuticals appoints Rainer Wessel as President and CEO

Rainer Wessel has been appointed President and Chief Executive Officer of GANYMED Pharmaceuticals AG (<http://www.ganymed-pharmaceuticals.com>), an independent biotechnology company with an initial focus on cancer. Wessel succeeds James A. Ratigan, an independent consultant who served as GANYMED's interim CEO since July 2003.

Wessel was with Axxima Pharmaceuticals AG, where he most recently served as President and Chief Executive Officer. Prior to that, he was responsible for intellectual property and licensing for Qiagen GmbH. He is a member of the Supervisory Board of ConoGenetix GmbH, and serves as a Senior Advisor to both the International Institute of Strategic Studies, and the Chemical and Biological Arms Control Institute, in Washington D.C.

'I am extremely pleased that Rainer joined the GANYMED team' said Felix Hofstetter, Chairman of GANYMED's Supervisory Board and Managing Partner of Nextech Venture, the Company's lead investor. 'He has proven skills in leading an entrepreneurial life science company, and has significant experience in the areas of business development and intellectual property'.

GANYMED uses its proprietary technology to rapidly discover, identify and validate highly selective, disease-specific cell-surface and intracellular antigens to accelerate the commercialization of highly effective therapeutics, initially in cancer, and also in the areas of infectious and autoimmune diseases.

Promotions announced at SurroMed

SurroMed (<http://www.surromed.com>), a company focusing on the discovery and application of biomarkers to improve the drug discovery and development process, has announced the promotion of Christopher Becker to the position of Vice President Chemistry and William Leschensky to the position of Vice President Intellectual property.

Prior to joining SurroMed in 2001, Becker was a staff scientist at SRI International and then a senior director of proteomic technology at Thermo Electron

Corporation. Howard Schulman, Vice President of Research and Development at SurroMed, commented: 'Chris and his team have developed a premier platform for biomarker discovery...this platform is critical to SurroMed's internal efforts to discover diagnostic biomarkers for a range of diseases....'

Leschensky joined SurroMed in 2000 as Director of Intellectual Property and prior to this he was an Associate at the law firm of Fish & Neave. Gordon Ringold, SurroMed's Chief Executive Officer and Chairman, commented: 'Bill has helped us create significant value as the leader of our intellectual property efforts...through his efforts, we have received, and expect to continue to receive in the future, a wide range of patents that should provide significant future value to SurroMed.'

Robert Mauro joins Able Laboratories as President and COO

Able Laboratories (<http://www.ablelabs.com>), a developer and manufacturer of generic pharmaceuticals, has announced the appointment of Robert Mauro to the position of President and Chief Operating Officer. He will also be appointed to the Company's Board of Directors.

Mauro has over 25 years of experience in both the brand and generic pharmaceutical industries. Prior to joining Able Laboratories, Mauro was Senior Director of Corporate Accounts for Ivax Corporation and then President of the North American Generics division of Taro Pharmaceuticals.

Commenting on his appointment, Mauro said: 'I am excited to be joining Able during such dynamic times...I have always enjoyed the challenge of building companies and look forward to working with Able's management team.'

Awards

Pharmaceutical Profiles receives award for early phase drug development innovation

UK-based company Pharmaceutical Profiles (<http://www.pharmprofiles.co.uk>) has been awarded the 2004 Frost & Sullivan Excellence in Technology Award in the field of drug discovery and development. This award is given to companies that have

pioneered the development and introduction of innovative technologies.

Pharmaceutical Profiles has been very active in adopting human microdosing studies in pre-clinical toxicology and ADME and using, in the area of drug delivery, sophisticated imaging studies in the development of inhaled products. Commenting on the award, Frost & Sullivan Industry Analyst Rajaram Sankaran said: 'Pharmaceutical Profiles clearly demonstrates leadership in integrating hi-tech medical imaging with sophisticated drug development processes to cut down the costs and time involved in early phase drug development...it's pioneering efforts and high level of technology development make Pharmaceutical Profiles a deserving recipient of this award.'

Michael Przybylski receives international award for excellence in mass spectrometry

An award sponsored by Applied Biosystems that recognises individuals who have made a significant contribution to the development and application of mass spectrometry in life sciences has been awarded to Michael Przybylski, head of the Laboratory of Analytical Chemistry at the University of Konstanz, Germany. Przybylski was selected by a scientific jury in recognition of his outstanding work in the area of protein analysis.

Commenting on the award, Jasna Peter-Katalinic, leader of the jury, said: 'In the past two decades, mass spectrometry has undergone important developments and its use in genomics and proteomics has effectively revolutionized life science research...Professor Przybylski has contributed to these developments from a very early stage. The results of his work have given extraordinary insight into the biologically active conformations of proteins and their pathophysiological changes, for example, in the course of Alzheimer's disease, where it has recently provided the elucidation of a new vaccine lead structure.'

The award was presented at a ceremony held at the UFZ Centre for Environmental Research, Leipzig-Halle GmbH at the Helmholtz Association, Germany.

People was written by
Christopher Watson